» Articles » PMID: 39118187

Effects of Cheese Ingestion on Muscle Mass and Strength in Possible Sarcopenia Women: an Open-label, Parallel-group Study

Overview
Publisher Biomed Central
Date 2024 Aug 8
PMID 39118187
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Nutrient-rich cheese supplements were demonstrated to have improvements in markers of sarcopenia in healthy elders. However, the potential effects of cheese in individuals with possible sarcopenia remain unknown.

Method: This 90-day randomized controlled trial (RCT) included 68 women aged 60-80 years with possible sarcopenia in China, who were randomly assigned to three groups: Control group (CG), Original cheese group (OG: 9.0 g protein; 322.8 mg calcium), and Golden cheese group (GG: 12.7 g protein; 802.1 mg calcium). OG and GG were instructed to consume their habitual diet along with 4 slices of supplied cheese, while CG was directed to maintain their usual dietary habits. Face-to-face interviews, anthropometric measurements, and blood sample collection were conducted at baseline, midway (60 days), and the end of the trial.

Result: At the end of the trial, the primary outcome, changes of Skeletal Muscle Mass Index (SMI) were found to be higher in OG (0.18 ± 0.02 kg/m) and GG (0.14 ± 0.02 kg/m) compared to CG (0.09 ± 0.02 kg/m). The secondary outcome, changes of handgrip strength were higher in GG (1.82 ± 4.16 kg) than CG (-0.61 ± 3.78 kg). There were no significant differences in makers for muscle function between three groups (P > 0.05). In the self-comparison, Creatinine/Cystatin C significantly increased in both OG and GG. In addition, OG had a significant increase in changes of free and total carnitine compared to CG.

Conclusion: Both golden and original cheese supplementation enhanced muscle strength and mass in older women with possible sarcopenia. The mechanism behind this effect may be linked to muscle cell energy metabolism.

Trial Registration: The present study was registered in the Chinese Clinical Trial Registry with the registration number ChiCTR2300078720 (retrospectively registered, 20231215).

References
1.
Lim W, Lewis J, Wong G, Turner R, Lim E, Thompson P . Comparison of estimated glomerular filtration rate by the chronic kidney disease epidemiology collaboration (CKD-EPI) equations with and without Cystatin C for predicting clinical outcomes in elderly women. PLoS One. 2014; 9(9):e106734. PMC: 4180254. DOI: 10.1371/journal.pone.0106734. View

2.
Chen L, Woo J, Assantachai P, Auyeung T, Chou M, Iijima K . Asian Working Group for Sarcopenia: 2019 Consensus Update on Sarcopenia Diagnosis and Treatment. J Am Med Dir Assoc. 2020; 21(3):300-307.e2. DOI: 10.1016/j.jamda.2019.12.012. View

3.
Ter Borg S, de Groot L, Mijnarends D, de Vries J, Verlaan S, Meijboom S . Differences in Nutrient Intake and Biochemical Nutrient Status Between Sarcopenic and Nonsarcopenic Older Adults-Results From the Maastricht Sarcopenia Study. J Am Med Dir Assoc. 2016; 17(5):393-401. DOI: 10.1016/j.jamda.2015.12.015. View

4.
Pfeifer M, Begerow B, Minne H, Suppan K, Fahrleitner-Pammer A, Dobnig H . Effects of a long-term vitamin D and calcium supplementation on falls and parameters of muscle function in community-dwelling older individuals. Osteoporos Int. 2008; 20(2):315-22. DOI: 10.1007/s00198-008-0662-7. View

5.
Wu G . Dietary protein intake and human health. Food Funct. 2016; 7(3):1251-65. DOI: 10.1039/c5fo01530h. View